2025-09-25 - Analysis Report
Okay, here's a report analyzing SDGR (Schrodinger Inc.), incorporating the data you provided.

**Report on SDGR (Schrodinger Inc.)**

**Company Overview:** Schrodinger Inc. is a company that develops software for drug discovery and materials science.

**1. Performance Analysis vs. S&P 500 (VOO)**

*   **SDGR Cumulative Return:** -34.87%
*   **VOO Cumulative Return:** 37.30%
*   **Spread (SDGR - VOO):** -117.0
*   **Spread Range:** Max: 66.2, Min: -117.9
*   **Relative Spread:** 0.5

**Analysis:** SDGR has significantly underperformed the S&P 500 over the analyzed period. The cumulative return difference is substantial (-117.0).  The relative spread of 0.5 indicates that SDGR is near the lowest end of its historical performance relative to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2020-2022  | -51.0%  | 98.1%   | -52.0%  | 0.1   | 1.4    |
| 2021-2023  | -29.0%  | 85.1%   | -40.0%  | 0.0   | 2.6    |
| 2022-2024  | 10.0%   | 85.1%   | -14.0%  | -0.0  | 1.4    |
| 2023-2025  | -5.0%   | 99.3%   | -45.0%  | -0.0  | 1.4    |

**Analysis:** The table shows a few concerning trends:
*   **Negative CAGR:**  Consistently negative Compound Annual Growth Rate (CAGR) across all periods, indicating a lack of sustained growth.
*   **High MDD:**  Very high Maximum Drawdown (MDD), signifying significant potential for losses.
*   **Negative Alpha:**  Large negative Alpha values suggest SDGR is underperforming its benchmark, even after accounting for market risk.
*   **Low/Negative Beta:** Beta values close to zero suggest SDGR's price is not strongly correlated with the overall market (S&P 500).

**2. Recent Price Action**

*   **Current Price:** 19.07
*   **Previous Close:** 19.06
*   **Change:** 0.05
*   **5-day Moving Average:** 19.384
*   **20-day Moving Average:** 19.2045
*   **60-day Moving Average:** 20.1436

**Analysis:** The current price is slightly above the previous close, suggesting a minor upward movement. However, the price is below all three moving averages (5, 20, and 60-day), which generally indicates a short-term downtrend or consolidation phase.

**3. Market Risk Indicators**

*   **MRI:** 0.434 (Medium Risk)
*   **RSI:** 48.01
*   **PPO:** 0.5287
*   **Hybrid Signal:** cash_0%_Buy 50% of cash (1 shares - Caution - MRI:0.42) (Cash Ratio: 0% on 2025-09-17)
*   **Recent (20-day) Relative Spread Change:** 0.5 (+) 단기상승
*   **Expected Return:** -5869.1%

**Analysis:**

*   **MRI:** The Market Risk Indicator (MRI) is at 0.434, placing it in the medium-risk category.
*   **RSI:** The RSI of 48.01 is close to neutral, not indicating oversold or overbought conditions.
*   **PPO:** A positive PPO suggests that the shorter-term moving average is above the longer-term moving average, indicating a potential upward trend.
*   **Hybrid Signal:**  The hybrid signal suggests a cautious approach, recommending a small purchase.
*   **Recent Relative Spread Change:** The increase in the relative spread suggests a recent improvement in SDGR's performance compared to VOO.
*   **Expected Return:** The extremely negative expected return (-5869.1%) is highly concerning and suggests significant underperformance relative to the S&P 500 over a long-term investment horizon.  This number is likely an anomaly, or a result of specific data used in the calculation, and should be investigated further.

The small change in price from the previous close (0.05) does not indicate a significant market reaction.

**4. Recent News & Significant Events**

*   **Schrödinger Reports Inducement Grants:** (Business Wire) - This is generally neutral to positive as it aligns incentives with employees.
*   **Schrödinger (SDGR): Evaluating Valuation as Market Sentiment Remains Quiet:** (Simply Wall St.) - Suggests uncertainty or lack of strong conviction in the current valuation.
*   **Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?:** (Zacks) - Points to potential upside based on analyst expectations.
*   **Schrödinger to Present at Morgan Stanley Global Healthcare Conference:** (Business Wire) - A standard corporate event, potentially positive for visibility.
*   **Schrödinger Announces Discontinuation of SGR-2921 Program:** (Business Wire) - This is generally negative, as it suggests a setback in their drug development pipeline.

**Analysis:** Recent news presents a mixed picture. Analyst optimism about a potential rally contrasts with concerns about valuation and the discontinuation of a drug program.

**4-2. Analyst Opinions**

*   **Consensus:** None (No rating provided)
*   **Mean Rating:** - (No rating provided)
*   **Number of Opinions:** 9
*   **Target Price:** Avg: 28.11 / High: 33.00 / Low: 19.00

**Analysis:** Analysts have provided price targets, with an average target price of $28.11, suggesting potential upside from the current price. However, the absence of a consensus rating and recent rating changes makes it difficult to determine the overall sentiment.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출    |
|------------|-------|---------|
| 2025-08-06 | -0.59 | 0.05 B$ |
| 2025-05-07 | -0.82 | 0.06 B$ |
| 2024-11-12 | -0.52 | 0.04 B$ |
| 2024-07-31 | -0.74 | 0.05 B$ |
| 2025-08-06 | -0.74 | 0.05 B$ |

**Analysis:** The earnings data shows consistent losses (negative EPS) and relatively stable revenue. This suggests that the company is not yet profitable and is still in a growth or development phase.

**6. Financial Information**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.05B  | 47.77%        |
| 2025-03-31 | $0.06B  | 52.26%        |
| 2024-12-31 | $0.09B  | 72.61%        |
| 2024-09-30 | $0.04B  | 50.24%        |
| 2024-06-30 | $0.05B  | 66.20%        |

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2025-06-30 | $0.34B   | -12.59%  |
| 2025-03-31 | $0.37B   | -16.01%  |
| 2024-12-31 | $0.42B   | -9.54%   |
| 2024-09-30 | $0.45B   | -8.49%   |
| 2024-06-30 | $0.47B   | -11.40%  |

**Analysis:**

*   **Revenue and Profit Margin:** While revenue fluctuates, profit margins are consistently positive, indicating the company can generate profit from its sales. However, it is also important to note that the company’s revenue is relatively small.
*   **Capital and Profitability:** Equity has been decreasing, and Return on Equity (ROE) is consistently negative, reflecting the company's inability to generate profits from its equity.

**7. Overall Summary**

SDGR has significantly underperformed the S&P 500. The financial data shows consistent losses, but positive profit margins, which indicates a problem with overall profitability despite efficient revenue generation. Recent news is mixed, with analyst optimism balanced by concerns and setbacks. The technical indicators present a neutral to slightly negative outlook.

**Key Takeaways:**

*   **Underperformance:** SDGR has struggled to deliver returns comparable to the broader market.
*   **Financial Concerns:** Consistent losses and negative ROE raise concerns about long-term financial sustainability.
*   **Mixed Signals:** Analyst sentiment is somewhat positive, but recent events (e.g., drug program discontinuation) and valuation concerns need to be considered.
*   **Risk:** The MRI indicates medium risk.

**Recommendation:**

Based on the provided data, a cautious approach is warranted. The company shows potential, but significant risks and challenges remain. Further research and due diligence are recommended before making any investment decisions. The reported expected return requires further investigation to understand the underlying calculation.
